Photo of Chris Boshoff from LinkedIn
Feb 1, 2024, 04:54
Chris Boshoff: The European Medicines Agency (EMA) has accepted our application in collaboration with Astellas Pharma US and Merck for a combination therapy for advanced Urothelial Cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn:
”The European Medicines Agency (EMA) has accepted our application in collaboration with Astellas Pharma US and Merck for a combination therapy for advanced Urothelial Cancer.
People living with bladder cancer in Europe face poor outcomes at the advanced stage, and innovative therapies are needed. This acceptance marks a significant milestone in our commitment to enhancing treatment options for people with bladder cancer.
Read more here.”
Source: Chris Boshoff/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14